Valerio Therapeutics Société anonyme (ALVIO.PA)
EUR 0.06
(0.16%)
EUR 0.06
(0.16%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.26 Million EUR | 36.38% |
| 2022 | 929 Thousand EUR | -74.85% |
| 2021 | 3.69 Million EUR | 2325.3% |
| 2020 | -166 Thousand EUR | -104.22% |
| 2019 | 3.93 Million EUR | -33.39% |
| 2018 | 5.91 Million EUR | -33.36% |
| 2017 | 8.87 Million EUR | 135.37% |
| 2016 | 3.76 Million EUR | 19.84% |
| 2015 | 3.14 Million EUR | -85.59% |
| 2014 | 21.83 Million EUR | 1715.61% |
| 2013 | 1.2 Million EUR | -67.08% |
| 2012 | 3.65 Million EUR | 157.81% |
| 2011 | -6.31 Million EUR | -129.15% |
| 2010 | 21.67 Million EUR | 203.64% |
| 2009 | 7.13 Million EUR | -9.19% |
| 2008 | 7.85 Million EUR | 126.05% |
| 2007 | 3.47 Million EUR | 997.87% |
| 2006 | 316.7 Thousand EUR | 496.7% |
| 2005 | -79.83 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -37 Thousand EUR | -104.98% |
| 2024 Q2 | -37 Thousand EUR | 0.0% |
| 2023 Q2 | -125 Thousand EUR | -14.16% |
| 2023 Q3 | 743 Thousand EUR | 694.4% |
| 2023 Q4 | 743 Thousand EUR | 0.0% |
| 2023 FY | 1.26 Million EUR | 36.38% |
| 2023 Q1 | -109.5 Thousand EUR | 93.2% |
| 2022 FY | 929 Thousand EUR | -74.85% |
| 2022 Q2 | -248 Thousand EUR | -104.96% |
| 2022 Q3 | 585.5 Thousand EUR | 336.09% |
| 2022 Q4 | -1.61 Million EUR | -374.98% |
| 2022 Q1 | -121 Thousand EUR | -106.41% |
| 2021 Q2 | -1.37 Million EUR | -798.23% |
| 2021 Q4 | 1.88 Million EUR | 14.4% |
| 2021 FY | 3.69 Million EUR | 2325.3% |
| 2021 Q1 | 197.5 Thousand EUR | 113.18% |
| 2021 Q3 | 1.64 Million EUR | 219.62% |
| 2020 FY | -166 Thousand EUR | -104.22% |
| 2020 Q3 | 267.5 Thousand EUR | 115.81% |
| 2020 Q4 | -1.49 Million EUR | -660.0% |
| 2020 Q2 | -1.69 Million EUR | -478.52% |
| 2020 Q1 | 447 Thousand EUR | 130.41% |
| 2019 Q3 | 1.19 Million EUR | 367.98% |
| 2019 Q4 | 194 Thousand EUR | -83.73% |
| 2019 Q2 | -445 Thousand EUR | -157.27% |
| 2019 FY | 3.93 Million EUR | -33.39% |
| 2019 Q1 | 777 Thousand EUR | -61.35% |
| 2018 Q1 | 945.5 Thousand EUR | -68.05% |
| 2018 FY | 5.91 Million EUR | -33.36% |
| 2018 Q4 | 2.01 Million EUR | 0.0% |
| 2018 Q3 | 2.01 Million EUR | 112.64% |
| 2018 Q2 | 945.5 Thousand EUR | 0.0% |
| 2017 Q4 | 2.95 Million EUR | 0.0% |
| 2017 FY | 8.87 Million EUR | 135.37% |
| 2017 Q1 | 1.47 Million EUR | 34.92% |
| 2017 Q2 | 1.47 Million EUR | 0.0% |
| 2017 Q3 | 2.95 Million EUR | 100.51% |
| 2016 Q3 | 1.09 Million EUR | 38.48% |
| 2016 FY | 3.76 Million EUR | 19.84% |
| 2016 Q1 | 790 Thousand EUR | -10.43% |
| 2016 Q2 | 790 Thousand EUR | 0.0% |
| 2016 Q4 | 1.09 Million EUR | 0.0% |
| 2015 Q1 | 690 Thousand EUR | -93.52% |
| 2015 Q2 | 690 Thousand EUR | 0.0% |
| 2015 FY | 3.14 Million EUR | -85.59% |
| 2015 Q4 | 882 Thousand EUR | 0.0% |
| 2015 Q3 | 882 Thousand EUR | 27.83% |
| 2014 Q1 | 269.5 Thousand EUR | 9.11% |
| 2014 FY | 21.83 Million EUR | 1715.61% |
| 2014 Q3 | 10.64 Million EUR | 3850.36% |
| 2014 Q2 | 269.5 Thousand EUR | 0.0% |
| 2014 Q4 | 10.64 Million EUR | 0.0% |
| 2013 FY | 1.2 Million EUR | -67.08% |
| 2013 Q2 | 354.23 Thousand EUR | 0.0% |
| 2013 Q1 | 354.23 Thousand EUR | 0.0% |
| 2013 Q3 | 246.99 Thousand EUR | -30.27% |
| 2013 Q4 | 246.99 Thousand EUR | 0.0% |
| 2012 FY | 3.65 Million EUR | 157.81% |
| 2011 FY | -6.31 Million EUR | -129.15% |
| 2010 FY | 21.67 Million EUR | 203.64% |
| 2009 FY | 7.13 Million EUR | -9.19% |
| 2008 FY | 7.85 Million EUR | 126.05% |
| 2007 FY | 3.47 Million EUR | 997.87% |
| 2006 FY | 316.7 Thousand EUR | 496.7% |
| 2005 FY | -79.83 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -105.016% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 67.629% |
| Adocia SA | 1.38 Million EUR | 8.52% |
| Aelis Farma SA | 12.35 Million EUR | 89.748% |
| Biophytis S.A. | -803 Thousand EUR | 257.783% |
| Advicenne S.A. | 1.42 Million EUR | 11.15% |
| genOway Société anonyme | 20.1 Million EUR | 93.697% |
| IntegraGen SA | 5.01 Million EUR | 74.752% |
| Medesis Pharma S.A. | -2.66 Million EUR | 147.546% |
| Neovacs S.A. | 29.31 Thousand EUR | -4222.167% |
| NFL Biosciences SA | -56.06 Thousand EUR | 2359.917% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 41.15% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 189.27% |
| Sensorion SA | 3.78 Million EUR | 66.551% |
| Theranexus Société Anonyme | -4.63 Million EUR | 127.314% |
| TME Pharma N.V. | -127 Thousand EUR | 1097.638% |
| Valbiotis SA | 2.66 Million EUR | 52.511% |
| TheraVet SA | -530.79 Thousand EUR | 338.698% |
| DBV Technologies S.A. | 4.15 Million EUR | 69.54% |
| Genfit S.A. | 28.22 Million EUR | 95.511% |
| GeNeuro SA | -293.8 Thousand EUR | 531.246% |
| Innate Pharma S.A. | -4.12 Million EUR | 130.745% |
| Inventiva S.A. | 17.5 Million EUR | 92.76% |
| MaaT Pharma SA | 1.65 Million EUR | 23.444% |
| MedinCell S.A. | 9.28 Million EUR | 86.359% |
| Nanobiotix S.A. | 36.2 Million EUR | 96.501% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 43.107% |
| Poxel S.A. | 1000.00 EUR | -126600.0% |
| GenSight Biologics S.A. | 3 Million EUR | 57.767% |
| Transgene SA | -28.4 Million EUR | 104.461% |
| Valneva SE | 52.83 Million EUR | 97.602% |